نتایج جستجو برای: anti-CD20

تعداد نتایج: 365619  

Journal: :international journal of hematology-oncology and stem cell research 0
mehrzad mirzania imam khomini hospital complex, vali-e-asr hospital, tehran university of medical sciences, tehran, iran. sedigheh khalili arak university of medical sciences, arak, iran. akbar hasanpoor arak university of medical sciences, arak, iran. ahmad reza shamshiri hematology-oncology and stem cell research center, tehran university of medical sciences, tehran, iran.

amegakaryocytic thrombocytopenia (amt) is a rare cause of acquired thrombocytopenia. the pathogenesis and treatment of amt is not clearly known. here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. the patient did not respond to intravenous immunoglob...

Background: Formation of secondary structure such as DNA hairpins or loops may influence molecular genetics methods and PCR based approaches necessary for genetic engineering, in addition to gene regulation. Materials and Methods: A polymerase chain reaction with splice overlap extension (SOE-PCR) was used to create fully synthetic 1F5 chimeric anti-CD20 heavy- and light-chain genes. The chi...

Journal: :International journal of oncology 2011
Michio Nishida Norio Uematsu Hideaki Kobayashi Yuka Matsunaga Shoko Ishida Minoru Takata Ohtsura Niwa Eduardo A Padlan Roland Newman

Rituximab (chimeric anti-CD20 mAb) is currently used in the treatment of B-NHL and B cell malignancies, alone or in combination with chemotherapy. However, subsets of patients do not initially respond and/or develop resistance to additional treatments. Hence, there is a need to develop more effective anti-CD20 mAbs that may improve clinical response. BM-ca is a novel humanized anti-CD20 mAb tha...

Journal: :research in molecular medicine 0
fatemeh khademi medical biology research center, p. o. box: 6714869914, sorkheh lizheh, kermanshah, iran pantea mohammadi medical biology research center, p. o. box: 6714869914, sorkheh lizheh, kermanshah, iran kheirollah yari medical biology research center, p. o. box: 6714869914, sorkheh lizheh, kermanshah, iran ali mostafaie medical biology research center, p. o. box: 6714869914, sorkheh lizheh, kermanshah, iran

background: formation of secondary structure such as dna hairpins or loops may influence molecular genetics methods and pcr based approaches necessary for genetic engineering, in addition to gene regulation. materials and methods: a polymerase chain reaction with splice overlap extension (soe-pcr) was used to create fully synthetic 1f5 chimeric anti-cd20 heavy- and light-chain genes. the chimer...

2013
Reiko Yamada Kristopher Steward Gataree Ngarmchamnanrith Ryan Trinh Sanjay Khare Raj Sachdev Iqbal Grewal Sherie Morrison John Timmerman

Results Anti-CD20-hIFNa induced stronger growth inhibition than rituximab, particularly against Burkitt and germinal center-type DLBCL NHLs. Tumor growth inhibition by anti-CD20-hIFNa was associated with substantial apoptosis in some cell lines. Anti-CD20-hIFNa exhibited potent ADCC activity against Daudi, Ramos, and Raji cells, identical to rituximab. Surprisingly, anti-CD20-hIFNa exhibited su...

Journal: :Blood 2011
Ai-Hong Zhang Jonathan Skupsky David W Scott

We herein tested the effect of B-cell depletion on tolerance induction to factor VIII (FVIII) in a mouse model of hemophilia A. Two subclasses of anti-mouse CD20 monoclonal antibodies with differential depletion effects were used. Thus, IgG1 anti-CD20 selectively depleted follicular B cells and spared marginal zone B cells, whereas IgG2a anti-CD20 efficiently depleted both. In FVIII primed mice...

2015
Laleh Khodadadi Qingyu Cheng Tobias Alexander Özen Sercan-Alp Jens Klotsche Andreas Radbruch Falk Hiepe Bimba F. Hoyer Adriano Taddeo Pierre Bobé

METHODS NZB/W F1 mice were treated with: 1) anti-CD20, 2) anti-CD20 plus bortezomib, 3) anti-CD20 plus anti-LFA-1/anti-VLA-4 blocking antibodies, 4) anti-CD20 plus bortezomib and anti-LFA-1/anti-VLA4 blocking antibodies. Short- and long-lived plasma cells including autoreactive cells in the bone marrow and spleen were enumerated by flow cytometry and ELISPOT seven days after treatment. Based on...

Journal: :Infection and immunity 2015
Waleed Elsegeiny Taylor Eddens Kong Chen Jay K Kolls

Anti-CD20 antibody therapy has been a useful medication for managing non-Hodgkin's lymphoma as well as autoimmune diseases characterized by autoantibody generation. CD20 is expressed during most developmental stages of B lymphocytes; thus, CD20 depletion leads to B-lymphocyte deficiency. As the drug has become more widely used, there has been an increase in the number of case reports of patient...

2013
Mareike Roscher Inis Hormann Oliver Leib Sebastian Marx Josue Moreno Erich Miltner Claudia Friesen

Radioimmunotherapy (RIT) is an emerging treatment option for non-Hodgkin lymphoma (NHL) producing higher overall response and complete remission rates compared with unlabelled antibodies. However, the majority of patients treated with conventional or myeloablative doses of radiolabelled antibodies relapse. The development of RIT with alpha-emitters is attractive for a variety of cancers because...

Journal: :Blood 2005
Stephen D Gillies Yan Lan Steven Williams Frank Carr Stephen Forman Andrew Raubitschek Kin-Ming Lo

We have engineered an anti-CD20-interleukin 2 (IL-2) immunocytokine (ICK) based on the Leu16 anti-CD20 antibody and have deimmunized both the variable (V) regions as well as the junction between the heavy (H) chain constant region and IL-2. Mutations were made to remove potential T-cell epitopes identified by in silico binding to major histocompatibility complex (MHC) class II molecules. The re...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید